Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from PureTech Health ( (GB:PRTC) ).
PureTech Health’s subsidiary, Gallop Oncology, announced promising new data from its Phase 1b trial of LYT-200, a monoclonal antibody, in treating relapsed/refractory acute myeloid leukemia (AML). The trial demonstrated significant clinical activity and a favorable safety profile, achieving a complete response rate of over 30% in combination with standard care, compared to typical rates of 6-12%. This positions LYT-200 as a potential new treatment option for AML, addressing an urgent unmet medical need. PureTech plans to advance LYT-200 into a Phase 2 trial and engage with regulatory authorities, with further data expected in late 2025 and early 2026.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £135.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s stock score reflects a mixed financial performance with strong liquidity but profitability challenges. Technical indicators suggest potential resistance, while valuation appears favorable. The earnings call provided a cautiously optimistic outlook, tempered by management changes and funding uncertainties.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a hub-and-spoke biotherapeutics company focused on transforming scientific innovation into value through a capital-efficient R&D model. It has developed numerous therapeutic candidates, including three that have received U.S. FDA approval. Gallop Oncology, a wholly-owned subsidiary of PureTech, is a clinical-stage biopharmaceutical company advancing novel treatments for hematologic malignancies, with its lead candidate being LYT-200 for acute myeloid leukemia (AML).
Average Trading Volume: 831,296
Technical Sentiment Signal: Strong Sell
Current Market Cap: £319M
For detailed information about PRTC stock, go to TipRanks’ Stock Analysis page.